Clinical Trial Update: Efficacy and Safety of Itolizumab in COVID-19 Complications [Phase 2]

View source ↗

Summary

Phase 2 trial update on Itolizumab for COVID-19 complications reports efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Respiratory Distress Syndrome

Drugs mentioned

• Itolizumab (Itolizumab)

Snippet

Sponsor: Biocon Limited | Conditions: Acute Respiratory Distress Syndrome, Cytokine Release Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-05-20